EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma

Toru Nakamura iD, Atsutaka Masuda iD, Dan Nakano, Keisuke Amano iD, Tomoya Sano iD, Masahito Nakano iD, Takumi Kawaguchi iD

Cells · 13.03.2025 · 14 (6) · 428

DOI: 10.3390/cells14060428 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 13.03.2025. Verfasst von Toru Nakamura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Fatty Liver. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMED, JSPS KAKENHI, MHLW Program for Basic and Clinical Research on Hepatitis Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer deaths worldwide. The etiology of HCC has now dramatically changed from viral hepatitis to metabolic dysfunction-associated steatotic liver disease (MASLD). The main pathogenesis of MASLD-related HCC is the hepatic lipid accumulation of hepatocytes, which causes chronic inflammation and the subsequent progression of hepatic fibrosis. Chronic hepatic inflammation generates oxidative stress and DNA damage in hepatocytes, which contribute to genomic instability, resulting in the development of HCC. Several metabolic and molecular pathways are also linked to chronic inflammation and HCC in MASLD. In particular, the MAPK and PI3K-Akt-mTOR pathways are upregulated in MASLD, promoting the survival and proliferation of HCC cells. In addition, MASLD has been reported to enhance the development of HCC in patients with chronic viral hepatitis infection. Although there is no approved medication for MASLD besides resmetirom in the USA, there are some preventive strategies for the onset and progression of HCC. Sodium-glucose cotransporter-2 (SGLT2) inhibitor, a class of medications, has been reported to exert anti-tumor effects on HCC by regulating metabolic reprogramming. Moreover, CD34-positive cell transplantation improves hepatic fibrosis by promoting intrahepatic angiogenesis and supplying various growth factors. Furthermore, exercise improves MASLD through an increase in energy consumption as well as changes in chemokines and myokines. In this review, we summarize the recent progress made in the pathogenic mechanisms of MASLD-associated HCC. Furthermore, we introduced new therapeutic strategies for preventing the development of HCC based on the pathogenesis of MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsFatty LiverHumansAnimals

Stichwörter der Autor:innen

CD34-positive cellsSGLT2 inhibitorfatty liverhepatocellular carcinomahepatomainflammationliver cancermetabolic dysfunction-associated steatotic liver diseasemyokinessteatosis

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.
  • Liver Cancer Research Division, Research Center for Innovative Cancer Therapy, Kurume University, 67 Asahi-Machi, Kurume 830-0011, Japan.
  • Fukuoka Consulting and Support Center for Liver Diseases, Kurume 830-0011, Japan.

ORCID-Profile: Toru Nakamura, Atsutaka Masuda, Keisuke Amano, Tomoya Sano, Masahito Nakano, Takumi Kawaguchi

Förderung

  • AMED
  • JSPS KAKENHI
  • MHLW Program for Basic and Clinical Research on Hepatitis Program

Zitieren

APA

Nakamura, T., Masuda, A., Nakano, D., Amano, K., Sano, T., Nakano, M., & Kawaguchi, T. (2025). Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma. Cells, 14(6), 428. https://doi.org/10.3390/cells14060428

Vancouver

Nakamura T, Masuda A, Nakano D, Amano K, Sano T, Nakano M, et al. Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma. Cells. 2025;14(6):428. doi:10.3390/cells14060428

BibTeX
@article{Nakamura2025,
  author = {Nakamura, Toru and Masuda, Atsutaka and Nakano, Dan and Amano, Keisuke and Sano, Tomoya and Nakano, Masahito and Kawaguchi, Takumi},
  title = {Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {6},
  pages = {428},
  doi = {10.3390/cells14060428}
}
Kostenlos starten →